Geode Capital Management LLC Purchases 43,074 Shares of CareDx, Inc. $CDNA

Geode Capital Management LLC boosted its holdings in shares of CareDx, Inc. (NASDAQ:CDNA) by 3.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,323,497 shares of the company’s stock after buying an additional 43,074 shares during the quarter. Geode Capital Management LLC owned approximately 2.38% of CareDx worth $25,864,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Sei Investments Co. increased its stake in shares of CareDx by 1.7% during the first quarter. Sei Investments Co. now owns 47,921 shares of the company’s stock worth $851,000 after purchasing an additional 816 shares during the period. Fuller & Thaler Asset Management Inc. raised its holdings in shares of CareDx by 3.9% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company’s stock worth $425,000 after buying an additional 900 shares in the last quarter. MCF Advisors LLC grew its position in CareDx by 292.9% in the second quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock valued at $26,000 after acquiring an additional 996 shares during the last quarter. Cetera Trust Company N.A grew its position in CareDx by 11.2% in the second quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock valued at $238,000 after acquiring an additional 1,225 shares during the last quarter. Finally, US Bancorp DE raised its stake in CareDx by 7.2% during the first quarter. US Bancorp DE now owns 18,403 shares of the company’s stock worth $327,000 after acquiring an additional 1,235 shares in the last quarter.

CareDx Trading Down 1.5%

Shares of CDNA opened at $17.55 on Friday. The stock’s 50-day moving average price is $15.42 and its two-hundred day moving average price is $15.62. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $26.37. The company has a market capitalization of $902.65 million, a PE ratio of 17.21 and a beta of 2.50.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.15. CareDx had a return on equity of 18.03% and a net margin of 17.97%.The company had revenue of $100.06 million during the quarter, compared to analysts’ expectations of $95.25 million. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. The business’s quarterly revenue was up 20.7% on a year-over-year basis. CareDx has set its FY 2025 guidance at EPS. Equities research analysts predict that CareDx, Inc. will post -0.9 EPS for the current fiscal year.

Analysts Set New Price Targets

CDNA has been the subject of several research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of CareDx in a research note on Tuesday. Wells Fargo & Company cut their price objective on CareDx from $19.00 to $14.00 and set an “equal weight” rating on the stock in a report on Friday, August 8th. William Blair began coverage on CareDx in a report on Tuesday, August 26th. They issued a “market perform” rating for the company. Wall Street Zen raised CareDx from a “sell” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Zacks Research upgraded CareDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 18th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, CareDx presently has a consensus rating of “Hold” and a consensus price target of $26.00.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.